Printer Friendly

INTERNATIONAL MUREX TECHNOLOGIES CORPORATION CLOSES EURO-EQUITY OFFERING

 INTERNATIONAL MUREX TECHNOLOGIES CORPORATION
 CLOSES EURO-EQUITY OFFERING
 TORONTO, Dec. 20 /PRNewswire/ -- International Murex Technologies Corporation (AMEX: MXX; TSE) has closed its previously announced Euro-Equity offering of 3,111,112 common shares for U.S. $35 million.
 The new securities, issued in Europe and elsewhere outside of North America in this offering, are subject to Securities and Exchange Commission (SEC) and Ontario Securities Commission (OSC) regulations which provide that the securities may not be traded in North America until Jan. 30, 1992. MXX now has approximately 14.0 million common shares outstanding.
 MXX has granted a non-transferable option to purchase up to an additional 888,888 common shares to the managers of the U.S. $35 million financing, led by Deacon Barclays de Zoete Wedd, at U.S. $11.25 per share aggregating up to an additional U.S. $10 million. The option is open for exercise until Jan. 8, 1992.
 Toronto-based MXX is an international medical diagnostic systems company dedicated to the development, manufacture and global marketing of cost-effective diagnostic tests for infectious diseases and products for the blood banking industry.
 -0- 12/20/91
 /CONTACT: C. Robert Cusick, president and chief executive officer, or Marcia M. Young of International Murex Technologies Corporation, 800-688-1332 or 416-408-4682/
 (MXX) CO: International Murex Technologies Corporation ST: Georgia, Ontario IN: MTC SU: OFR


BR-TG -- AT006 -- 4472 12/20/91 15:31 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 20, 1991
Words:228
Previous Article:PGI INCORPORATED UNABLE TO REACH AGREEMENT WITH LENDING GROUP FOR PROPOSED RESTRUCTURING PLAN
Next Article:SPRAGUE TECHNOLOGIES DECLARES DIVIDEND
Topics:


Related Articles
INTERNATIONAL MUREX IN ACQUISITION DISCUSSION WITH WELLCOME
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES EURO-EQUITY FINANCING
INTERNATIONAL MUREX AWARDED MAJOR HCV PRODUCT CONTRACT FROM GERMAN RED CROSS; CONTRACT ENHANCES MUREX'S GROWING POSITION IN BLOOD VIROLOGY
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ADVISES HOLDERS OF UPCOMING WARRANT EXPIRATION
INTERNATIONAL MUREX AND DIGENE EXPAND DNA PROBE COLLABORATION
INTERNATIONAL MUREX LAUNCHES ENHANCED HIV TEST INTO GLOBAL MARKETS
INTERNATIONAL MUREX TECHNOLOGIES REPORTS FIRST QUARTER 1995 RESULTS
INTERNATIONAL MUREX'S SUBSIDIARY RECEIVES INTERIM CASH SECURITY RULING FROM BRITISH COURT
International Murex Signs Worldwide Distribution License With Eurogenetics

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters